Diazoxide In the Management Of Hypoglycemic Neonates (DIMOHN)

U

University of Saskatchewan

Status and phase

Unknown
Phase 3
Phase 2

Conditions

Hypoglycemia
Infant, Diabetic Mother
Infant, Large for Gestational Age
Infant, Newborn, Diseases
Pregnancy in Diabetics

Treatments

Drug: Ora-plus
Drug: Diazoxide

Study type

Interventional

Funder types

Other

Identifiers

NCT00994149
Bio-REB #08-151
HC Control Number: 126963

Details and patient eligibility

About

Diazoxide is an oral hyperglycemic medication. Diazoxide has been proven effective for treating hypoglycemia in infants and children with some types of persistent hyperinsulinemic hypoglycemia. The mechanism of action results in decreased insulin secretion. One of the causes of hypoglycemia in infants of diabetic mothers occurs due to a transient hyperinsulinemic state postnatally. The investigators have clinical experience and success using diazoxide in their unit for patients with hypoglycemia not adequately managed with intravenous (iv) dextrose and enteral supplementation. In this randomized controlled study the investigators expect that by using diazoxide as the initial treatment for infants of diabetic mothers with asymptomatic hypoglycemia (blood glucose of 2.5 to 2.0mmol/L), the investigators will be able to decrease the number of infants requiring an intravenous by at least thirty percent.

Enrollment

100 estimated patients

Sex

All

Ages

Under 12 hours old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Infants of diabetic mothers (IDMs) or infants weighing >90%
  • Hypoglycemia: two consecutive blood glucose measurements <2.6mol/L and >1.9mmol/L in the first twelve hours of life
  • > 36 weeks gestational age

Exclusion criteria

  • Infants with symptomatic hypoglycemia (regardless of value
  • Infants who meet criteria for intravenous dextrose according to the Canadian Pediatric Society (CPS) position statement
  • Infants with contraindications for enteral feeds and/or medications

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

100 participants in 2 patient groups, including a placebo group

Diazoxide
Experimental group
Description:
Infants in this are will receive 10mg/kg/d of diazoxide divided and given every eight hours
Treatment:
Drug: Diazoxide
Ora-plus
Placebo Comparator group
Description:
Liquid suspension modified to match intervention. Given every eight hours. Provided in shielded syringes.
Treatment:
Drug: Ora-plus

Trial contacts and locations

0

Loading...

Central trial contact

Jennifer M Toye, MD, FRCP(C); Koravangattu Sankaran, MD, BS, FRCPC, F.C.C.M.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems